• 1. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 2. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 3. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 4. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 5. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034

Introduction to 3-(3-Fluorophenyl)-1H-pyrazole-4-carboxylic Acid (CAS No. 879996-69-7)

3-(3-Fluorophenyl)-1H-pyrazole-4-carboxylic acid, identified by its CAS number 879996-69-7, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic organic compound has garnered attention due to its unique structural properties and potential applications in drug development. The presence of a fluorophenyl moiety and a carboxylic acid functional group at the 4-position of the pyrazole ring imparts distinct chemical and pharmacological characteristics, making it a valuable scaffold for designing novel therapeutic agents.

The compound's structure, characterized by a pyrazole core substituted with a fluorine atom at the 3-position of the phenyl ring and a carboxylic acid group at the 4-position, offers a versatile platform for chemical modifications. These modifications can be tailored to enhance specific pharmacokinetic properties, such as solubility, bioavailability, and metabolic stability. The fluorine atom, in particular, is known for its ability to influence molecular interactions with biological targets, often improving binding affinity and selectivity.

In recent years, there has been a surge in research focused on developing new therapeutic agents with improved efficacy and reduced side effects. Pyrazole derivatives have emerged as promising candidates in this endeavor due to their diverse biological activities. Among these derivatives, 3-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid has shown particular promise in preclinical studies. Its ability to modulate various biological pathways makes it a candidate for treating a range of diseases, including inflammatory disorders, infectious diseases, and even certain types of cancer.

The carboxylic acid group in this compound provides multiple opportunities for further functionalization. It can be esterified to enhance oral bioavailability or amidated to create peptide-like structures. Additionally, the carboxylate anion form can participate in coordination chemistry, allowing for the development of metal-based drug conjugates. These conjugates have shown potential in targeted therapy, where the metal component can be used to deliver the active pharmaceutical ingredient directly to diseased cells.

Recent advancements in computational chemistry have further facilitated the design and optimization of compounds like 3-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid. Molecular docking studies have been instrumental in identifying potential binding sites on biological targets, allowing researchers to fine-tune the structure for maximum efficacy. These studies have revealed that the fluorophenyl group plays a crucial role in interactions with enzymes and receptors, often enhancing binding affinity through hydrophobic interactions and dipole-dipole forces.

The pharmacological profile of this compound has been extensively studied in vitro and in vivo. Initial experiments have demonstrated its ability to inhibit key enzymes involved in inflammatory pathways, such as COX-2 and LOX. This makes it a potential candidate for developing anti-inflammatory drugs with fewer side effects compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Furthermore, its interaction with certain protein kinases has been explored, suggesting its potential use in oncology research.

The synthesis of 3-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid involves multi-step organic reactions that require precise control over reaction conditions. The introduction of the fluorine atom into the phenyl ring is particularly challenging due to its high reactivity and tendency to undergo side reactions. However, advances in synthetic methodologies have made it possible to achieve high yields and purity levels necessary for pharmaceutical applications. Techniques such as palladium-catalyzed cross-coupling reactions have been employed to construct the pyrazole core efficiently.

The compound's solubility profile is another critical factor that influences its pharmaceutical applicability. While the carboxylic acid group enhances water solubility compared to hydrophobic pyrazole derivatives, further modifications may be needed to optimize solubility for oral or injectable formulations. Researchers are exploring strategies such as prodrug design or co-crystallization with hydrotropes to improve solubility without compromising efficacy.

In conclusion, 3-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid represents a promising candidate for drug development due to its unique structural features and versatile chemical properties. Its potential applications span multiple therapeutic areas, including inflammation management, infectious diseases, and cancer treatment. Continued research into its synthesis, pharmacology, and formulation will likely lead to novel therapeutic agents that address unmet medical needs.

• 54952-71-5(3-methyl-5-phenyl-1h-pyrazole-4-carboxylic acid)
• 306936-57-2(3-(4-Fluorophenyl)-1H-pyrazole-4-carbaldehyde)
• 875664-59-8(3-(3,5-Difluorophenyl)-1H-pyrazole-4-carboxaldehyde)
• 161398-15-8(3-(3-Fluorophenyl)-1H-pyrazole-4-carbaldehyde)
• 879996-75-5(3-(2,4-Dimethylphenyl)-1H-pyrazole-4-carboxylic acid)
• 1017784-36-9(1H-Pyrazole-4-carboxylicacid, 3-(4-fluorophenyl)-, methyl ester)
• 5504-65-4(3-Phenyl-1H-pyrazole-4-carboxylic acid)
• 618383-44-1(3-(4-fluorophenyl)-1H-pyrazole-4-carboxylic Acid)
• 879996-72-2(3-(3-methylphenyl)-1H-pyrazole-4-carboxylic Acid)
• 879996-73-3(5-(2-Fluorophenyl)-1H-pyrazole-4-carboxylic Acid)